() () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () () ()

Tag Archives: ACB

Aurora Cannabis and EnWave Corporation Enter Global Licensing Arrangements

April 26, 2019 (GLOBE NEWSWIRE) -- Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) and EnWave Corporation  (TSX-V:ENW) (FSE:E4U) (“EnWave”) announced today that the companies have entered into a royalty-bearing commercial license agreement (the “License”), providing Aurora with the exclusive rights to EnWave’s patented Radiant Energy Vacuum (REV™) drying technology for the production of cannabis materials in the European Union, excluding Portugal.
Read more

Hempco Secures C$4 Million Loan Facility from Aurora

Hempco Food and Fiber Inc. ("Hempco" or "the Company") (TSX-V: HEMP) today announced that it has entered into a loan agreement (the "Loan Agreement") with Aurora Cannabis Inc. (NYSE: ACB) (TSX:  ACB) (Frankfurt: 21P; WKN: A1C4WM) ("Aurora") pursuant to which Aurora has agreed to lend to Hempco up to C$4 million (the "Loan").
Read more

Aurora Bolsters Anandia’s Testing Capabilities Through Acquisition of Chemi Pharmaceutical

April 25, 2019 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM) announced today that the company has signed a binding share purchase agreement whereby Aurora has acquired all of the issued and outstanding common shares of privately-held Chemi Pharmaceutical Inc, ("Chemi"), an Ontario-based laboratory specialized in providing high quality analytics services to the pharmaceutical and cannabis industries, in a cash and share transaction (the "Transaction") comprised of an undisclosed cash payment and share consideration of 83,299 shares paid on closing and 41,649 payable upon achievement of certain Chemi milestones.
Read more

Aurora Cannabis Provides Update On German Cannabis Production Tender

April 18, 2019 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) confirmed today that, further to its press release dated April 5, 2019, the public appeal process related to the German cannabis production tender has been completed, and Aurora's contract with  the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte BfArM) has now been finalized.
Read more
Get $50 in free trades.